Reportstack provider of premium market research reports and databases announces the addition of Global Pharma business contacts Database & European Pharma business contacts database to their offering.
The Global & European Pharmaceutical Databases 2011 are the most current and up-to-date pharma database in the market. While there are many contact lists available on the internet, none of them are accurate and focused on illustrating business contacts from different strategic processes and key departments within the pharma industry. This database is greatly essential for marketers and sales professional that are stuck in their business development activities as they do not have valid and accurate information on their target contacts at the pharmaceutical industry.
Includes 5000+ business contacts from the Top 50 pharma companies in Europe & across the globe.
Includes primary contacts related to Market research, Sales, IT, Supply chain and Procurement, Finance, Human Resources, Clinical research, Oncology, Biomarkers and Quality.
Information includes name, designation, location, phone no. and working email.
Includes contacts from multiple company locations.
Detailed company profiles and executive bios available on request
This database is extremely beneficial for:
Independent consulting houses targeting the pharma industry for market research and consulting
Supply and logistics companies who target the massive worldwide transportation and supply chain requirements of the pharma industry
Information technology and software firms who target the pharma companies to promote their CRM, MIS and ERP related products and services
Firms which deal in packaging material for pharma and healthcare products.
Marketing and branding firms who are looking to cater to the huge potential of the pharma and biotech market.
Recruitment agencies and consultancies.
Chemical manufacturers that deal in pharmaceutical raw materials.
According to Barcatech, a sales acceleration company and creator of these databases, an average 15 minutes were spent in collecting Intel of one contact. These databases are created using the best in practice primary research tools and Barcatech have spent more than 1000 manual hours in building this accurate list of business contacts so that the customers save money and also a lot of time by using the Global & European Pharma companies' database.
For more information about the European pharma companies' database visit: http://www.reportstack.com/product/23597/european-pharmaceutical-database-2011.html.
Visit Reportstack's blog
Showing posts with label healthcare. Show all posts
Showing posts with label healthcare. Show all posts
Monday, 1 August 2011
Friday, 29 July 2011
Autoimmune Diseases-Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis
Reportstack announces the addition of Autoimmune Diseases - Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis market research report to their offering. This report adds to the growing portfolio of strategic reports on the Multiple Sclerosis market and Rheumatoid Arthritis market.
This report focuses on current and pipeline candidate therapeutics and their respective targets for three autoimmune diseases and answers such questions as:
Who are the companies with active development programs for these diseases?
Which targets are actively being investigated and what new targets are coming forward?
Who has candidates in active Phase III and Phase II clinical trials?
What does the overall target activity map, from launched drug to preclinical research candidates look like?
Where are next generation biological therapeutics found across these three diseases?
Are small molecules a significant portion of the development activity?
Autoimmune Diseases: Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis describes pipeline activities across these three diseases. We report on the:
Development pipelines for each disease providing information on company and licensee involvement.
Active Phase III and Phase II clinical trials and provide study completion dates.
Targets involved across the spectrum of launched and preclinical activities.
Competition among companies developing therapeutics targeting the same or related physiology.
Pace of development activities across these three diseases.
Small or specialty companies with innovative therapy development programs.
More information about this latest autoimmune diseases market research report can be found at: http://www.reportstack.com/product/22552/autoimmune-diseases-pipelines-for-crohns-disease-multiple-sclerosis-and-rheumatoid-arthritis-.html
More information about Pharma & Healthcare market research reports can be found here: http://www.reportstack.com/category/11/pharma-healthcare.html
This report focuses on current and pipeline candidate therapeutics and their respective targets for three autoimmune diseases and answers such questions as:
Who are the companies with active development programs for these diseases?
Which targets are actively being investigated and what new targets are coming forward?
Who has candidates in active Phase III and Phase II clinical trials?
What does the overall target activity map, from launched drug to preclinical research candidates look like?
Where are next generation biological therapeutics found across these three diseases?
Are small molecules a significant portion of the development activity?
Autoimmune Diseases: Pipelines for Crohn's Disease, Multiple Sclerosis and Rheumatoid Arthritis describes pipeline activities across these three diseases. We report on the:
Development pipelines for each disease providing information on company and licensee involvement.
Active Phase III and Phase II clinical trials and provide study completion dates.
Targets involved across the spectrum of launched and preclinical activities.
Competition among companies developing therapeutics targeting the same or related physiology.
Pace of development activities across these three diseases.
Small or specialty companies with innovative therapy development programs.
More information about this latest autoimmune diseases market research report can be found at: http://www.reportstack.com/product/22552/autoimmune-diseases-pipelines-for-crohns-disease-multiple-sclerosis-and-rheumatoid-arthritis-.html
More information about Pharma & Healthcare market research reports can be found here: http://www.reportstack.com/category/11/pharma-healthcare.html
Thursday, 28 July 2011
Digital Dentistry Markets Expected to Reach $1.2 Billion by 2017: States New Report on Reportstack
Reportstack announces the addition of Digital Dentistry Market Shares, Strategies, and Forecasts, Worldwide, 2011 to 2017 market research report to their offering. This latest report predicts that digital dentistry markets for low iron glass currently valuated at $444.6 million are expected to reach $1.2 billion by 2017. Growth is expected to achieve marked improvements in the efficiency of dentist clinician care delivery and the longevity of crowns and bridges.
The markets for the digital dentistry products are highly competitive. The competitive factors are features, reliability, brand name recognition, distribution network, customer service, and price. The product cycles are shortening. Vendors work to develop, complete testing, obtain regulatory approval and sell commercial quantities of new products in a timely manner.
The digital dental CAD/CAM systems, digital dental x-ray, laser, and scanner markets are characterized by changing customer needs. Change relates to efficiencies provided by the technology. As the technology becomes improved, systems are more modern units are offered. Vendors are positioning to extend core technologies to new applications and anticipate and respond to emerging standards, business models, service delivery methods and other technological changes.
Digital Dental CAD/CAM systems are priced to sell equipment and software. Sales include the parts and printing services business. Services suppliers are operating on a local level. Success depends on the ability to enhance existing products and services. New products and services are introduced on a timely basis. Vendors seek to provide cost-effective solutions.
According the Susan Eustis, principal author of the study, "factors driving this market include achievement of higher capability for efficient care delivery by dentists. Fewer visits are needed to install crowns and bridges, creating incentive and ROI for practicing dentists to move to digital dentistry. Increased demand for better dentistry and more aesthetic outcomes is a significant market trend. Systems implementations are dependent on patients having disposable income that they are willing to invest in their teeth."
Find more information about this report at: http://www.reportstack.com/product/23593/digital-dentistry-market-shares-strategies-and-forecasts-worldwide-2011-to-2017.html
Find reports related to Pharma and Healthcare at http://www.reportstack.com/category/11/pharma-healthcare.html.
You can find other Dental Market Research and Medical Devices market research reports at Reportstack's official website.
The markets for the digital dentistry products are highly competitive. The competitive factors are features, reliability, brand name recognition, distribution network, customer service, and price. The product cycles are shortening. Vendors work to develop, complete testing, obtain regulatory approval and sell commercial quantities of new products in a timely manner.
The digital dental CAD/CAM systems, digital dental x-ray, laser, and scanner markets are characterized by changing customer needs. Change relates to efficiencies provided by the technology. As the technology becomes improved, systems are more modern units are offered. Vendors are positioning to extend core technologies to new applications and anticipate and respond to emerging standards, business models, service delivery methods and other technological changes.
Digital Dental CAD/CAM systems are priced to sell equipment and software. Sales include the parts and printing services business. Services suppliers are operating on a local level. Success depends on the ability to enhance existing products and services. New products and services are introduced on a timely basis. Vendors seek to provide cost-effective solutions.
According the Susan Eustis, principal author of the study, "factors driving this market include achievement of higher capability for efficient care delivery by dentists. Fewer visits are needed to install crowns and bridges, creating incentive and ROI for practicing dentists to move to digital dentistry. Increased demand for better dentistry and more aesthetic outcomes is a significant market trend. Systems implementations are dependent on patients having disposable income that they are willing to invest in their teeth."
Find more information about this report at: http://www.reportstack.com/product/23593/digital-dentistry-market-shares-strategies-and-forecasts-worldwide-2011-to-2017.html
Find reports related to Pharma and Healthcare at http://www.reportstack.com/category/11/pharma-healthcare.html.
You can find other Dental Market Research and Medical Devices market research reports at Reportstack's official website.
Wednesday, 27 July 2011
Reportstack: Advanced Drug Delivery Technologies: Enabling Drug Reformulations & Administration Routes
Reportstack has announced the addition of Insight Pharma's 'Advanced Drug Delivery Technologies: Enabling Drug Reformulations and Administration Routes' to their offering.
Exciting developments are occurring in the field of alternative drug delivery—a phrase that describes the reformulation of drugs to enable lower doses, more convenient delivery routes, and supplemental therapeutic indications. This report presents an overview of these developments, describes the options that new formulation technologies are creating, and explores the medical and commercial perspectives.
Discussed in this report:
The enabling role of medical devices in drug delivery technology
Drug delivery applications of nanotechnology
How advanced drug delivery can overcome biological barriers
Alternative delivery modalities for biotechnology-derived drugs
Nucleic acid delivery technologies
Resurgence of transdermal delivery technology
Role of alternative delivery in drug lifecycle management
Corporate showcase of 29 drug delivery companies including NanoViricides, Starpharma Holdings, CyDex Pharmaceuticals, Nektar Therapeutics, SurModics, MannKind, NanoBio, and Vyteris
The pharmaceutical industry is paying attention to aspects of innovation and business development that it has always employed occasionally but not systematically. These involve finding new uses for known active ingredients, by repurposing them to entirely new therapeutic fields or by leveraging modern formulation technology to significantly improve their properties.
We begin by describing the main routes of drug delivery (oral, injection/infusion, and transdermal), their pros and cons, and the environment in which they are deployed. We also explain that “alternative” drug delivery is not so much about fundamentally different “roads into the unknown” that have not been taken before, but about new dimensions of the known routes. In other words, what we call alternative drug delivery consists of clever technical advancements along what ultimately are the known routes.
The enabling role of medical devices in drug delivery technology is addressed next. Drug-eluting stents and other implantable drug delivery devices are presented, as well as externally applied devices. Next, drug delivery applications of nanotechnology are introduced. When combined with appropriate targeting moieties, drug-coated nanoparticles, drug-encapsulating liposomes and nanotubes, and tree-like dendrimers enable organ and tissue targeting.
After a discussion of ways in which drug delivery can overcome anatomical and functional barriers, the report turns to alternative delivery modalities for peptides, proteins, and antibodies. These biotechnology-derived drugs were formerly administered by injection alone, but today, solutions for inhaled, transdermal, and even oral delivery are available or under investigation for most established products.
Next we consider nucleic acid delivery technologies, which are not actually “alternative” but are initially enabling for their novel cargoes, since unprotected or untargeted delivery of gene therapies or RNAi is inconceivable. We then move on to developments in transdermal delivery technology, which includes active systems where delivery is driven by microneedles or energy applied via ultrasound or lasers.
We then explore the role of alternative delivery in drug lifecycle management. Case studies demonstrate how cleverly applied technologies can reinvigorate drugs that have lost patent protection or have not fully exploited their potential. We also present unique technologies with broad applicability in alternative drug delivery. Regulatory pathways and timelines for obtaining patents for the new products are addressed.
Selected drug delivery firms, their technological approaches, pipelines, and collaborations are profiled. We conclude with an outlook to what we call the “Preprogrammed Rise of Alternative Drug Delivery”—an unavoidable development driven by the fact that lifecycle management and recouping of value from existing resources will continue to rule the pharmaceutical industry’s business throughout the 2010sReportstack.com has announced the addition of Insight Pharma's 'Commercializing Biomarkers in Therapeutic and Diagnostic Applications' to their offering.
Buy Now
http://www.reportstack.com/product/22558/advanced-drug-delivery-technologies-enabling-drug-reformulations-and-administration-routes.html
Browse other Pharma & Healthcare Industry related reports at:
http://www.reportstack.com/category/11/pharma-healthcare.html
Exciting developments are occurring in the field of alternative drug delivery—a phrase that describes the reformulation of drugs to enable lower doses, more convenient delivery routes, and supplemental therapeutic indications. This report presents an overview of these developments, describes the options that new formulation technologies are creating, and explores the medical and commercial perspectives.
Discussed in this report:
The enabling role of medical devices in drug delivery technology
Drug delivery applications of nanotechnology
How advanced drug delivery can overcome biological barriers
Alternative delivery modalities for biotechnology-derived drugs
Nucleic acid delivery technologies
Resurgence of transdermal delivery technology
Role of alternative delivery in drug lifecycle management
Corporate showcase of 29 drug delivery companies including NanoViricides, Starpharma Holdings, CyDex Pharmaceuticals, Nektar Therapeutics, SurModics, MannKind, NanoBio, and Vyteris
The pharmaceutical industry is paying attention to aspects of innovation and business development that it has always employed occasionally but not systematically. These involve finding new uses for known active ingredients, by repurposing them to entirely new therapeutic fields or by leveraging modern formulation technology to significantly improve their properties.
We begin by describing the main routes of drug delivery (oral, injection/infusion, and transdermal), their pros and cons, and the environment in which they are deployed. We also explain that “alternative” drug delivery is not so much about fundamentally different “roads into the unknown” that have not been taken before, but about new dimensions of the known routes. In other words, what we call alternative drug delivery consists of clever technical advancements along what ultimately are the known routes.
The enabling role of medical devices in drug delivery technology is addressed next. Drug-eluting stents and other implantable drug delivery devices are presented, as well as externally applied devices. Next, drug delivery applications of nanotechnology are introduced. When combined with appropriate targeting moieties, drug-coated nanoparticles, drug-encapsulating liposomes and nanotubes, and tree-like dendrimers enable organ and tissue targeting.
After a discussion of ways in which drug delivery can overcome anatomical and functional barriers, the report turns to alternative delivery modalities for peptides, proteins, and antibodies. These biotechnology-derived drugs were formerly administered by injection alone, but today, solutions for inhaled, transdermal, and even oral delivery are available or under investigation for most established products.
Next we consider nucleic acid delivery technologies, which are not actually “alternative” but are initially enabling for their novel cargoes, since unprotected or untargeted delivery of gene therapies or RNAi is inconceivable. We then move on to developments in transdermal delivery technology, which includes active systems where delivery is driven by microneedles or energy applied via ultrasound or lasers.
We then explore the role of alternative delivery in drug lifecycle management. Case studies demonstrate how cleverly applied technologies can reinvigorate drugs that have lost patent protection or have not fully exploited their potential. We also present unique technologies with broad applicability in alternative drug delivery. Regulatory pathways and timelines for obtaining patents for the new products are addressed.
Selected drug delivery firms, their technological approaches, pipelines, and collaborations are profiled. We conclude with an outlook to what we call the “Preprogrammed Rise of Alternative Drug Delivery”—an unavoidable development driven by the fact that lifecycle management and recouping of value from existing resources will continue to rule the pharmaceutical industry’s business throughout the 2010sReportstack.com has announced the addition of Insight Pharma's 'Commercializing Biomarkers in Therapeutic and Diagnostic Applications' to their offering.
Buy Now
http://www.reportstack.com/product/22558/advanced-drug-delivery-technologies-enabling-drug-reformulations-and-administration-routes.html
Browse other Pharma & Healthcare Industry related reports at:
http://www.reportstack.com/category/11/pharma-healthcare.html
Reportstack: Commercializing Biomarkers in Therapeutic and Diagnostic Applications
Reportstack has announced the addition of Insight Pharma's 'Commercializing Biomarkers in Therapeutic and Diagnostic Applications' to their offering
Biomarkers feature in thousands of published articles each year, evidencing the high level of interest and research in this field. This report focuses on issues that must be addressed to utilize this growing knowledge about biomarkers and successfully commercialize them in therapeutic and diagnostic applications. Included in this publication:
Biomarker definitions and guidelines for their development and validation
Applications of biomarkers in oncology, cardiology, neurology, drug safety, and other areas
Selected companies in the biomarker research products/tools and services market
Strategies for successful commercialization of biomarkers in the therapeutics and diagnostics markets
Forty key companies to watch, plus the activities of 175 companies that are commercializing biomarkers and/or systems for their detection and measurement
Expert interviews
Biomarkers can be valuable tools in clinical diagnostics as well as in therapeutic discovery and development. They can be used to predict response to therapy or risk of side effects for personalized medicine applications. Additional types include predisposition, screening, diagnostic, prognostic, toxicity, pharmacodynamic, and other biomarkers.
Commercializing Biomarkers in Therapeutic and Diagnostic Applications: From Development to Validated Product focuses on questions that must be addressed to successfully take advantage of the potential of biomarkers. The analysis begins with a discussion of biomarker definitions and related terms, followed by an overview of the different types and applications of biomarkers. This is followed by brief summaries of the range of technologies that may be used to discover, identify, and measure biomarkers. Discussion then turns to a very critical issue: biomarker validation. This includes a discussion of recommendations and guidelines that have been made by many different groups and organizations for biomarker development and validation.
Next, examples are provided of the wide range of current and potential emerging applications of biomarkers in different fields such as oncology, cardiology, neurology, safety, and others. An examination of the market for research products (tools) and services in the field of biomarkers includes a discussion of selected companies and their activities, plus agreements and acquisitions in this area.
As part of a dual focus, Commercializing Biomarkers in Therapeutic and Diagnostic Applications: From Development to Validated Product then analyzes biomarker strategies for diagnostic companies, considering what is required to successfully commercialize biomarkers in the diagnostics market. Discussion includes: identification of novel biomarkers, analytical validation of diagnostic tests for new biomarkers, clinical validation and clinical utility of biomarkers, research and other information needs regarding biomarkers, models and options for diagnostic companies in the field of personalized medicine, strategic options for the delivery of novel biomarker assays, health economics and reimbursement, and other issues.
Similarly, this report also focuses on biomarker strategies for therapeutic development. This includes a discussion of the potential roles of biomarkers in various aspects of drug development, validation of biomarkers, regulatory issues, options for companies developing drug/diagnostic combinations, health economics and reimbursement in personalized medicine, and other issues. Also included is a compilation of agreements between pharmaceutical and diagnostic companies.
Forty key companies to watch are identified, plus 175 companies that are commercializing biomarkers and/or systems for their detection and measurement. The report concludes with Insight Pharma Reports’ interviews with experts in this field.
Buy Now
http://www.reportstack.com/product/22555/commercializing-biomarkers-in-therapeutic-and-diagnostic-applications.html
Browse other Pharma & Healthcare Industry related reports at:
http://www.reportstack.com/category/11/pharma-healthcare.html
Biomarkers feature in thousands of published articles each year, evidencing the high level of interest and research in this field. This report focuses on issues that must be addressed to utilize this growing knowledge about biomarkers and successfully commercialize them in therapeutic and diagnostic applications. Included in this publication:
Biomarker definitions and guidelines for their development and validation
Applications of biomarkers in oncology, cardiology, neurology, drug safety, and other areas
Selected companies in the biomarker research products/tools and services market
Strategies for successful commercialization of biomarkers in the therapeutics and diagnostics markets
Forty key companies to watch, plus the activities of 175 companies that are commercializing biomarkers and/or systems for their detection and measurement
Expert interviews
Biomarkers can be valuable tools in clinical diagnostics as well as in therapeutic discovery and development. They can be used to predict response to therapy or risk of side effects for personalized medicine applications. Additional types include predisposition, screening, diagnostic, prognostic, toxicity, pharmacodynamic, and other biomarkers.
Commercializing Biomarkers in Therapeutic and Diagnostic Applications: From Development to Validated Product focuses on questions that must be addressed to successfully take advantage of the potential of biomarkers. The analysis begins with a discussion of biomarker definitions and related terms, followed by an overview of the different types and applications of biomarkers. This is followed by brief summaries of the range of technologies that may be used to discover, identify, and measure biomarkers. Discussion then turns to a very critical issue: biomarker validation. This includes a discussion of recommendations and guidelines that have been made by many different groups and organizations for biomarker development and validation.
Next, examples are provided of the wide range of current and potential emerging applications of biomarkers in different fields such as oncology, cardiology, neurology, safety, and others. An examination of the market for research products (tools) and services in the field of biomarkers includes a discussion of selected companies and their activities, plus agreements and acquisitions in this area.
As part of a dual focus, Commercializing Biomarkers in Therapeutic and Diagnostic Applications: From Development to Validated Product then analyzes biomarker strategies for diagnostic companies, considering what is required to successfully commercialize biomarkers in the diagnostics market. Discussion includes: identification of novel biomarkers, analytical validation of diagnostic tests for new biomarkers, clinical validation and clinical utility of biomarkers, research and other information needs regarding biomarkers, models and options for diagnostic companies in the field of personalized medicine, strategic options for the delivery of novel biomarker assays, health economics and reimbursement, and other issues.
Similarly, this report also focuses on biomarker strategies for therapeutic development. This includes a discussion of the potential roles of biomarkers in various aspects of drug development, validation of biomarkers, regulatory issues, options for companies developing drug/diagnostic combinations, health economics and reimbursement in personalized medicine, and other issues. Also included is a compilation of agreements between pharmaceutical and diagnostic companies.
Forty key companies to watch are identified, plus 175 companies that are commercializing biomarkers and/or systems for their detection and measurement. The report concludes with Insight Pharma Reports’ interviews with experts in this field.
Buy Now
http://www.reportstack.com/product/22555/commercializing-biomarkers-in-therapeutic-and-diagnostic-applications.html
Browse other Pharma & Healthcare Industry related reports at:
http://www.reportstack.com/category/11/pharma-healthcare.html
Reportstack: Therapeutic Protein Production: A Changing Landscape
Reportstack has announced the addition of Insight Pharma's 'Therapeutic Protein Production: A Changing Landscape' to their offering.
A Changing Landscape examines the implications of and advances in upstream and downstream operations used in the production of therapeutic proteins. Improvements in protein yields per unit volume, the significance of introducing disposables throughout the process and the shift to animal extracts-free culture media are three of the major themes covered by this report. The impact of global competition, lower barriers to entry and the shift in the production bottleneck from upstream to downstream unit operations are presented together with likely shifts impacting the production outlook over the next five years. More than a dozen tables and figures in this report summarize the report’s findings.
Some of the topics highlighted in the report:
Pros and cons of animal cell culture
Development of alternative production cell lines
Improving protein production per volume of culture media
Impact of disposables on cost and availability of proteins
Bottlenecks appear on the downstream side of production
Shift away from capital spending on fixed, reusable infrastructure
Tackling biosimilar regulatory questions
Dimensions of Asian and EU competition
Bioprocessing is the branch of biotechnology dealing with the production and purification of biological materials of commercial interest. This report focuses on the wide range of disciplines applied to the rapid and economical production of protein molecules. While most antibody biologics are anti-cancer agents, there are a number of other disease indications, including immune dysfunction, infectious disease and mental illness management, fueling the growth of this therapeutic area.
Trends in the upstream and downstream areas of monoclonal antibody production are encouraging and should help control the manufacturing costs of monoclonal antibodies. As indicated in this report, an increase in the use of disposables in upstream and downstream unit operations is underway. This shift away from fixed, reusable equipment is driving change in the industry, making available to cash-strapped small companies workable product quantities at affordable costs and allowing companies to enter clinical trials with promising but higher-risk, second-tier candidates. The availability of disposables has caused major biotech companies to question their strategy of large capital investments in reusable equipment.
This report identifies the continuing upstream versus downstream gap problem for the industry. Progress toward producing more protein per unit volume of culture medium has moved more rapidly and is placing pressure on the rates at which these proteins can be purified at the downstream end. This overall expansion has motivated regulatory agencies in Europe to redefine intellectual property guidelines and rules governing biosimilars. Legislation governing biosimilars has been passed in the US as part of the recent 2010 health care legislation.
This report also evaluates rising concern over the threat of Asian and European competition to the American biotech industry
Buy Now
http://www.reportstack.com/product/22576/therapeutic-protein-production-a-changing-landscape.html
Browse other Pharma and Healthcare Industry related reports at:
http://www.reportstack.com/category/11/pharma-healthcare.html
A Changing Landscape examines the implications of and advances in upstream and downstream operations used in the production of therapeutic proteins. Improvements in protein yields per unit volume, the significance of introducing disposables throughout the process and the shift to animal extracts-free culture media are three of the major themes covered by this report. The impact of global competition, lower barriers to entry and the shift in the production bottleneck from upstream to downstream unit operations are presented together with likely shifts impacting the production outlook over the next five years. More than a dozen tables and figures in this report summarize the report’s findings.
Some of the topics highlighted in the report:
Pros and cons of animal cell culture
Development of alternative production cell lines
Improving protein production per volume of culture media
Impact of disposables on cost and availability of proteins
Bottlenecks appear on the downstream side of production
Shift away from capital spending on fixed, reusable infrastructure
Tackling biosimilar regulatory questions
Dimensions of Asian and EU competition
Bioprocessing is the branch of biotechnology dealing with the production and purification of biological materials of commercial interest. This report focuses on the wide range of disciplines applied to the rapid and economical production of protein molecules. While most antibody biologics are anti-cancer agents, there are a number of other disease indications, including immune dysfunction, infectious disease and mental illness management, fueling the growth of this therapeutic area.
Trends in the upstream and downstream areas of monoclonal antibody production are encouraging and should help control the manufacturing costs of monoclonal antibodies. As indicated in this report, an increase in the use of disposables in upstream and downstream unit operations is underway. This shift away from fixed, reusable equipment is driving change in the industry, making available to cash-strapped small companies workable product quantities at affordable costs and allowing companies to enter clinical trials with promising but higher-risk, second-tier candidates. The availability of disposables has caused major biotech companies to question their strategy of large capital investments in reusable equipment.
This report identifies the continuing upstream versus downstream gap problem for the industry. Progress toward producing more protein per unit volume of culture medium has moved more rapidly and is placing pressure on the rates at which these proteins can be purified at the downstream end. This overall expansion has motivated regulatory agencies in Europe to redefine intellectual property guidelines and rules governing biosimilars. Legislation governing biosimilars has been passed in the US as part of the recent 2010 health care legislation.
This report also evaluates rising concern over the threat of Asian and European competition to the American biotech industry
Buy Now
http://www.reportstack.com/product/22576/therapeutic-protein-production-a-changing-landscape.html
Browse other Pharma and Healthcare Industry related reports at:
http://www.reportstack.com/category/11/pharma-healthcare.html
Subscribe to:
Posts (Atom)